Abstract

Background: Phosphodiesterase 7 (PDE7) is a high affinity CAMP-specific PDE whose functional role in T cells has been the subject of some controversy. Recent findings on tissue distribution, however, support the hypothesis that PDE7 could be a good target for the treatment of airway diseases, T-cell related diseases or even CNS disorders. Objective/method: This review discloses recent discoveries of selective PDE7 and PDE4/PDE7 dual inhibitors with special emphasis on their potential for neurological and inflammatory diseases. Conclusion: PDE7 inhibitors constitute a new approach to be explored for the treatment of neurodegenerative disorders.